Nottingham, UK-headquartered XenoGesis has appointed business development consultant Sabrina Mogle to drive the contract research organisation’s growth in the US.
Bringing expertise in business and corporate development in the biotech and pharma industries, Mogle will spearhead XenoGesis’ US business development strategy and industry awareness profile.
Richard Weaver, managing director of XenoGesis, said: “Sabrina’s appointment supports our growth strategy to open up the US market. We already have a number of clients in the US and have identified the opportunity to grow our business further in the US.
“We are excited to welcome Sabrina to the team and her experience, knowledge and understanding of drug development and regulatory affair in the US will be a valuable addition to our business.”
Currently, Mogle serves as chief executive officer of RareMoon Consulting, a non-clinical development and regulatory affairs consulting firm specialising in orphan drugs she co-founded earlier this year.
She has previously held director-level roles at US biotechs NovusLife and Cote Orphan, and US CROs Toxikon Corporation and XenoTech.
Mogle said: “XenoGesis is an exciting, fast-growing and ambitious business and is developing an enviable reputation in the preclinical DMPK space for its consultative approach with clients.
“I am delighted to be part of the team and play my part in supporting the next stage growth.”